Emergent BioSolutions reported Q3 2024 revenues of $293.8 million, up 9% year-over-year, driven by a 62% increase in MCM Product sales to $174.2 million. Net income was $114.8 million compared to a net loss of $263.4 million in Q3 2023. The company recognized a $60.8 million gain from the sale of RSDL to SERB for $75 million.The company strengthened its financial position by entering into a new $250 million Term Loan Agreement and a $100 million Revolving Credit Agreement. Commercial Product sales declined 33% to $95.3 million due to the transition from prescription to over-the-counter NARCAN. Services revenue remained flat at $14.3 million as the company continued to restructure its CDMO business.Operating expenses decreased 55% to $229.3 million, reflecting lower employee-related costs from restructuring initiatives and absence of prior year's goodwill impairment charge. The company ended the quarter with $149.9 million in cash and believes it has adequate liquidity to fund operations for at least the next twelve months, having alleviated previous going concern doubts.

Emergent BioSolutions reported Q3 2024 revenues of $293.8 million, up 9% year-over-year, driven by a 62% increase in MCM Product sales to $174.2 million. Net income was $114.8 million compared to a net loss of $263.4 million in Q3 2023. The company recognized a $60.8 million gain from the sale of RSDL to SERB for $75 million.The company strengthened its financial position by entering into a new $250 million Term Loan Agreement and a $100 million Revolving Credit Agreement. Commercial Product sales declined 33% to $95.3 million due to the transition from prescription to over-the-counter NARCAN. Services revenue remained flat at $14.3 million as the company continued to restructure its CDMO business.Operating expenses decreased 55% to $229.3 million, reflecting lower employee-related costs from restructuring initiatives and absence of prior year's goodwill impairment charge. The company ended the quarter with $149.9 million in cash and believes it has adequate liquidity to fund operations for at least the next twelve months, having alleviated previous going concern doubts.